Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

GlobeNewswireJan 9 21:00

BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Announces Target Price $12

Futu NewsJan 6 19:34 · Ratings

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswireNov 27, 2024 05:00

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Simply Wall StNov 16, 2024 20:45

BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating

Futu NewsNov 13, 2024 23:33 · Ratings

Express News | Acumen Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $12 From $14

BreakingsNov 13, 2024 23:14